GRAIL (GRAL) Q3 2026 Earnings Call Transcript

GRAIL reported Q3 2026 revenue of $37.5 million, up 4% year over year, as screening revenue rose 14% and test volume increased 24% to more than 56,000; promotional pricing brought average selling price to about $660 per test. Net loss widened 16% to $103.6 million, adjusted gross margin fell to 42% from 55%, and adjusted EBITDA loss increased 29% to $92.6 million. Management lowered full-year 2026 revenue-growth guidance to 17%–21%, while maintaining cash-burn guidance of no more than $300 million and reporting $788.7 million in cash and marketable securities, with runway into 2029. The company cited a positive FDA advisory committee vote and expects an FDA decision by early Q1 2027, but said competitive pressure and negative NHS-Galleri headlines tempered Q3 growth.

Analysis

GRAL’s key near-term question is whether discount-led volume converts into durable, profitable repeat testing—not whether it can generate a temporary volume lift. Lower ASPs and higher commercial spend are already pressuring unit economics; management’s projected COGS improvement depends on scale, while the resumed Illumina royalty is a near-term margin headwind. Verify realized ASP, repeat-test rates, and gross margin together: volume growth alone would be a poor validation of the strategy.

The early-Q1 FDA decision is a catalyst, not a reimbursement event. A favorable decision could improve provider confidence and payer access, but label limitations or consent requirements could constrain ordering channels; even a broad label does not establish coverage, pricing, or clinical-guideline adoption. The less favorable NHS trial endpoints leave room for competitors to challenge the commercial interpretation of the evidence. The market may be underpricing the gap between regulatory clearance and meaningful reimbursement, and overpricing approval as an immediate sales inflection.

Over the next 1–3 months, watch the FDA label, Q4 demand and 2027 guidance; over 6–18 months, payer decisions, repeat behavior, and scale-driven cost reductions determine whether the model can approach attractive margins. ILMN may benefit when the royalty resumes, but the cited quarterly amount is not enough to establish material consolidated earnings impact. The thesis weakens if GRAL sustains volume without further ASP erosion and demonstrates improving gross margin, or if FDA approval is followed quickly by credible coverage.

Key Decisions for Investors

• Avoid chasing GRAL ahead of the FDA decision; treat it as a binary catalyst with a potentially long monetization lag. Reassess after the label is disclosed rather than assuming the advisory vote guarantees broad commercial access.
• For existing GRAL exposure, monitor ASP, repeat-test rates, and gross margin as a linked scorecard. Reduce conviction if volume growth continues while pricing and margins deteriorate, or if 2027 guidance fails to show a path from promotion to durable demand.
• Keep ILMN’s royalty resumption on the earnings watchlist, but do not use it alone as a long thesis until filings clarify the royalty’s ongoing amount and materiality to consolidated results.
• Track payer coverage and ordering restrictions as the next confirmation points. A broad FDA label without subsequent coverage, or evidence that Epic integrations fail to lift repeat ordering, would falsify the expected adoption inflection.